We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

63 hedge funds and large institutions have $80.7M invested in LENZ Therapeutics in 2022 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 28

0% more funds holding

Funds holding: 63 → 63 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.52% less ownership

Funds ownership: 8.96% → 7.44% (-1.5%)

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

57% less capital invested

Capital invested by funds: $186M → $80.7M (-$105M)

72% less call options, than puts

Call options by funds: $59K | Put options by funds: $210K

Holders
63
Holders Change
–
Holders Change %
0%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
29
Increased
11
Reduced
14
Closed
28
Calls
$59K
Puts
$210K
Net Calls
-$151K
Net Calls Change
-$151K

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$3.5M
2
Renaissance Technologies
Renaissance Technologies
New York
+$2.51M
3
LCM
Laurion Capital Management
New York
+$1.83M
4
Two Sigma Investments
Two Sigma Investments
New York
+$1.39M
5
Millennium Management
Millennium Management
New York
+$1.28M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$13.8M
2
RSCM
Rock Springs Capital Management
Maryland
-$9.13M
3
VA
VR Adviser
New York
-$8.22M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.41M
5
BlackRock
BlackRock
New York
-$3.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
Manulife (Manufacturers Life Insurance)
76
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$64.2K -1,799 Closed
ProShare Advisors
77
ProShare Advisors
Maryland
– -$60K -1,649 Closed
Walleye Capital
78
Walleye Capital
New York
– -$57K -1,604 Closed
Barclays
79
Barclays
United Kingdom
– -$44K -1,254 Closed
SO
80
STRS Ohio
Ohio
– -$35K -1,000 Closed
Allspring Global Investments
81
Allspring Global Investments
North Carolina
– -$30K -845 Closed
AB
82
Amalgamated Bank
New York
– -$21K -597 Closed
Legal & General Group
83
Legal & General Group
United Kingdom
– -$14K -404 Closed
MLICM
84
Metropolitan Life Insurance Company (MetLife)
New York
– -$12K -337 Closed
Royal Bank of Canada
85
Royal Bank of Canada
Ontario, Canada
– -$9K -259 Closed
AIP
86
Ameritas Investment Partners
Nebraska
– -$6K -178 Closed
PHK
87
Point72 Hong Kong
Hong Kong
– -$5K -147 Closed
CS
88
Credit Suisse
Switzerland
– +$45 +2 New
SFG
89
Steward Financial Group
Texas
– +$45 +2 New
EI
90
Ellevest Inc
New York
– +$446 +20 New
1 2 3
4

LENZ Hedge Fund Activity: Q2 2022 in Review

63 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2022, worth a combined $80.7M — down 57% from $186M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new LENZ positions and 28 closed out — a net gain of 1 holder — while 11 added to existing stakes and 14 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $3.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $13.8M sold.

  • 63 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $80.7M of LENZ Therapeutics stock for Q2 2022, down 57% quarter-over-quarter.
  • 29 funds opened new LENZ Therapeutics positions in Q2 2022 and 28 closed out, a net change of +1 holder.
  • The largest LENZ Therapeutics buyer in Q2 2022 was Tang Capital Management, an estimated $3.5M added.
  • The largest LENZ Therapeutics seller in Q2 2022 was RA Capital Management, an estimated $13.8M sold.

Based on aggregated 13F filings for Q2 2022.